Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.
Identifieur interne : 003138 ( PubMed/Corpus ); précédent : 003137; suivant : 003139Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.
Auteurs : Chee Khoon Lee ; Sarah Lord ; Tami Grunewald ; Val Gebski ; Anne-Claire Hardy-Bessard ; Jalid Sehouli ; Kathrine Woie ; Mark Heywood ; Christian Schauer ; Ignace Vergote ; Giovanni Scambia ; Annamaria Ferrero ; Philipp Harter ; Eric Pujade-Lauraine ; Michael FriedlanderSource :
- Gynecologic oncology [ 1095-6859 ] ; 2015.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Carboplatin (administration & dosage), Carboplatin (adverse effects), Combined Modality Therapy, Disease-Free Survival, Doxorubicin (administration & dosage), Doxorubicin (adverse effects), Doxorubicin (analogs & derivatives), Female, Humans, Middle Aged, Neoplasm Recurrence, Local (drug therapy), Neoplasm Recurrence, Local (surgery), Ovarian Neoplasms (drug therapy), Ovarian Neoplasms (surgery), Paclitaxel (administration & dosage), Paclitaxel (adverse effects), Polyethylene Glycols (administration & dosage), Polyethylene Glycols (adverse effects), Prognosis, Survival Rate, Young Adult.
- MESH :
- chemical , administration & dosage : Carboplatin, Doxorubicin, Paclitaxel, Polyethylene Glycols.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Doxorubicin, Paclitaxel, Polyethylene Glycols.
- chemical , analogs & derivatives : Doxorubicin.
- drug therapy : Neoplasm Recurrence, Local, Ovarian Neoplasms.
- surgery : Neoplasm Recurrence, Local, Ovarian Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adolescent, Adult, Aged, Aged, 80 and over, Combined Modality Therapy, Disease-Free Survival, Female, Humans, Middle Aged, Prognosis, Survival Rate, Young Adult.
Abstract
The role of secondary cytoreductive surgery (SCR) in platinum-sensitive recurrent ovarian cancer (ROC) remains controversial. The overall survival (OS) benefits for surgery reported in observational studies may be due to the selection of patients with better prognosis.
DOI: 10.1016/j.ygyno.2014.09.017
PubMed: 25281492
Links to Exploration step
pubmed:25281492Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.</title><author><name sortKey="Lee, Chee Khoon" sort="Lee, Chee Khoon" uniqKey="Lee C" first="Chee Khoon" last="Lee">Chee Khoon Lee</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia; Cancer Care Centre, St George Hospital, Grey Street, Kogarah, NSW 2230, Australia. Electronic address: chee.lee@ctc.usyd.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Lord, Sarah" sort="Lord, Sarah" uniqKey="Lord S" first="Sarah" last="Lord">Sarah Lord</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Grunewald, Tami" sort="Grunewald, Tami" uniqKey="Grunewald T" first="Tami" last="Grunewald">Tami Grunewald</name><affiliation><nlm:affiliation>Cancer Care Centre, St George Hospital, Grey Street, Kogarah, NSW 2230, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Gebski, Val" sort="Gebski, Val" uniqKey="Gebski V" first="Val" last="Gebski">Val Gebski</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hardy Bessard, Anne Claire" sort="Hardy Bessard, Anne Claire" uniqKey="Hardy Bessard A" first="Anne-Claire" last="Hardy-Bessard">Anne-Claire Hardy-Bessard</name><affiliation><nlm:affiliation>Clinique Armoricaine de Radiologie, 21 Rue du Vieux Séminaire, 22015 Saint-Brieuc Cedex, France.</nlm:affiliation></affiliation></author><author><name sortKey="Sehouli, Jalid" sort="Sehouli, Jalid" uniqKey="Sehouli J" first="Jalid" last="Sehouli">Jalid Sehouli</name><affiliation><nlm:affiliation>Department of Gynecology, European Competence Center for Ovarian Cancer, Charité-University Medicine of Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Woie, Kathrine" sort="Woie, Kathrine" uniqKey="Woie K" first="Kathrine" last="Woie">Kathrine Woie</name><affiliation><nlm:affiliation>Department of Obstetrics and Gynecology, Haukeland University Hospital, N-5021 Bergen, Norway.</nlm:affiliation></affiliation></author><author><name sortKey="Heywood, Mark" sort="Heywood, Mark" uniqKey="Heywood M" first="Mark" last="Heywood">Mark Heywood</name><affiliation><nlm:affiliation>Vancouver Acute Department of Gynaecology, Rm 6207D Diamond Health Care Centre, 2775 Laurel St., Vancouver, BC V5Z 1M9, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Schauer, Christian" sort="Schauer, Christian" uniqKey="Schauer C" first="Christian" last="Schauer">Christian Schauer</name><affiliation><nlm:affiliation>Barmherzige Brüder Graz, Marschallgasse 12, 8020 Graz, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name><affiliation><nlm:affiliation>Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Leuven Cancer Institute, University Hospital Leuven, Herestraat 49, B-3000 Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Scambia, Giovanni" sort="Scambia, Giovanni" uniqKey="Scambia G" first="Giovanni" last="Scambia">Giovanni Scambia</name><affiliation><nlm:affiliation>Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, 00168 Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ferrero, Annamaria" sort="Ferrero, Annamaria" uniqKey="Ferrero A" first="Annamaria" last="Ferrero">Annamaria Ferrero</name><affiliation><nlm:affiliation>Academic Department Gynecologic Oncology, Mauriziano Hospital, Largo Turati 62, 10128 Torino, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Harter, Philipp" sort="Harter, Philipp" uniqKey="Harter P" first="Philipp" last="Harter">Philipp Harter</name><affiliation><nlm:affiliation>Department of Gynecology & Gynecologic Oncology, Klinikum Essen Mitte, Henricistrasse 92, 45136 Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation><nlm:affiliation>Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu, Oncologie, 1 Place du Parvis Notre-Dame, 75004 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name><affiliation><nlm:affiliation>Medical Oncology, Prince of Wales Hospital, Barker Street, Randwick, NSW 2013, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25281492</idno><idno type="pmid">25281492</idno><idno type="doi">10.1016/j.ygyno.2014.09.017</idno><idno type="wicri:Area/PubMed/Corpus">003138</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003138</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.</title><author><name sortKey="Lee, Chee Khoon" sort="Lee, Chee Khoon" uniqKey="Lee C" first="Chee Khoon" last="Lee">Chee Khoon Lee</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia; Cancer Care Centre, St George Hospital, Grey Street, Kogarah, NSW 2230, Australia. Electronic address: chee.lee@ctc.usyd.edu.au.</nlm:affiliation></affiliation></author><author><name sortKey="Lord, Sarah" sort="Lord, Sarah" uniqKey="Lord S" first="Sarah" last="Lord">Sarah Lord</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Grunewald, Tami" sort="Grunewald, Tami" uniqKey="Grunewald T" first="Tami" last="Grunewald">Tami Grunewald</name><affiliation><nlm:affiliation>Cancer Care Centre, St George Hospital, Grey Street, Kogarah, NSW 2230, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Gebski, Val" sort="Gebski, Val" uniqKey="Gebski V" first="Val" last="Gebski">Val Gebski</name><affiliation><nlm:affiliation>National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hardy Bessard, Anne Claire" sort="Hardy Bessard, Anne Claire" uniqKey="Hardy Bessard A" first="Anne-Claire" last="Hardy-Bessard">Anne-Claire Hardy-Bessard</name><affiliation><nlm:affiliation>Clinique Armoricaine de Radiologie, 21 Rue du Vieux Séminaire, 22015 Saint-Brieuc Cedex, France.</nlm:affiliation></affiliation></author><author><name sortKey="Sehouli, Jalid" sort="Sehouli, Jalid" uniqKey="Sehouli J" first="Jalid" last="Sehouli">Jalid Sehouli</name><affiliation><nlm:affiliation>Department of Gynecology, European Competence Center for Ovarian Cancer, Charité-University Medicine of Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Woie, Kathrine" sort="Woie, Kathrine" uniqKey="Woie K" first="Kathrine" last="Woie">Kathrine Woie</name><affiliation><nlm:affiliation>Department of Obstetrics and Gynecology, Haukeland University Hospital, N-5021 Bergen, Norway.</nlm:affiliation></affiliation></author><author><name sortKey="Heywood, Mark" sort="Heywood, Mark" uniqKey="Heywood M" first="Mark" last="Heywood">Mark Heywood</name><affiliation><nlm:affiliation>Vancouver Acute Department of Gynaecology, Rm 6207D Diamond Health Care Centre, 2775 Laurel St., Vancouver, BC V5Z 1M9, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Schauer, Christian" sort="Schauer, Christian" uniqKey="Schauer C" first="Christian" last="Schauer">Christian Schauer</name><affiliation><nlm:affiliation>Barmherzige Brüder Graz, Marschallgasse 12, 8020 Graz, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Vergote, Ignace" sort="Vergote, Ignace" uniqKey="Vergote I" first="Ignace" last="Vergote">Ignace Vergote</name><affiliation><nlm:affiliation>Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Leuven Cancer Institute, University Hospital Leuven, Herestraat 49, B-3000 Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Scambia, Giovanni" sort="Scambia, Giovanni" uniqKey="Scambia G" first="Giovanni" last="Scambia">Giovanni Scambia</name><affiliation><nlm:affiliation>Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, 00168 Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ferrero, Annamaria" sort="Ferrero, Annamaria" uniqKey="Ferrero A" first="Annamaria" last="Ferrero">Annamaria Ferrero</name><affiliation><nlm:affiliation>Academic Department Gynecologic Oncology, Mauriziano Hospital, Largo Turati 62, 10128 Torino, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Harter, Philipp" sort="Harter, Philipp" uniqKey="Harter P" first="Philipp" last="Harter">Philipp Harter</name><affiliation><nlm:affiliation>Department of Gynecology & Gynecologic Oncology, Klinikum Essen Mitte, Henricistrasse 92, 45136 Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation><nlm:affiliation>Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu, Oncologie, 1 Place du Parvis Notre-Dame, 75004 Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name><affiliation><nlm:affiliation>Medical Oncology, Prince of Wales Hospital, Barker Street, Randwick, NSW 2013, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Gynecologic oncology</title><idno type="eISSN">1095-6859</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Carboplatin (administration & dosage)</term><term>Carboplatin (adverse effects)</term><term>Combined Modality Therapy</term><term>Disease-Free Survival</term><term>Doxorubicin (administration & dosage)</term><term>Doxorubicin (adverse effects)</term><term>Doxorubicin (analogs & derivatives)</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (drug therapy)</term><term>Neoplasm Recurrence, Local (surgery)</term><term>Ovarian Neoplasms (drug therapy)</term><term>Ovarian Neoplasms (surgery)</term><term>Paclitaxel (administration & dosage)</term><term>Paclitaxel (adverse effects)</term><term>Polyethylene Glycols (administration & dosage)</term><term>Polyethylene Glycols (adverse effects)</term><term>Prognosis</term><term>Survival Rate</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carboplatin</term><term>Doxorubicin</term><term>Paclitaxel</term><term>Polyethylene Glycols</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Carboplatin</term><term>Doxorubicin</term><term>Paclitaxel</term><term>Polyethylene Glycols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Doxorubicin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasm Recurrence, Local</term><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Neoplasm Recurrence, Local</term><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Combined Modality Therapy</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Prognosis</term><term>Survival Rate</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The role of secondary cytoreductive surgery (SCR) in platinum-sensitive recurrent ovarian cancer (ROC) remains controversial. The overall survival (OS) benefits for surgery reported in observational studies may be due to the selection of patients with better prognosis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25281492</PMID><DateCreated><Year>2015</Year><Month>01</Month><Day>02</Day></DateCreated><DateCompleted><Year>2015</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-6859</ISSN><JournalIssue CitedMedium="Internet"><Volume>136</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Gynecologic oncology</Title><ISOAbbreviation>Gynecol. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.</ArticleTitle><Pagination><MedlinePgn>18-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ygyno.2014.09.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0090-8258(14)01344-4</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The role of secondary cytoreductive surgery (SCR) in platinum-sensitive recurrent ovarian cancer (ROC) remains controversial. The overall survival (OS) benefits for surgery reported in observational studies may be due to the selection of patients with better prognosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using data from the CALYPSO trial, OS of patients who had SCR was compared to those treated with chemotherapy alone. Multivariate analyses were performed to adjust for prognostic factors. We also tested for an interaction between baseline prognostic groupings and the benefit of surgery.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 975 patients randomised in CALYPSO, 19% had SCR and 80% had chemotherapy alone. OS was longer for the SCR group than for chemotherapy alone (median, 49.9 vs. 29.7 months; adjusted hazard ratio (HR), 0.68; P = 0.004). For patients with SCR, the 3-year OS was 72% for those with no measurable disease, and 28% if residual tumour was larger than 5 cm. Patients with good prognostic features benefited the most from SCR (HR 0.43; P < 0.001). The benefit of SCR was less in patients with poorer prognostic features (test of trend P < 0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">SCR was associated with improved OS in platinum-sensitive ROC, particularly in patients with favourable prognostic characteristics. However, these findings may be due to selection bias, and hence randomised trials are still essential.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chee Khoon</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia; Cancer Care Centre, St George Hospital, Grey Street, Kogarah, NSW 2230, Australia. Electronic address: chee.lee@ctc.usyd.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunewald</LastName><ForeName>Tami</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cancer Care Centre, St George Hospital, Grey Street, Kogarah, NSW 2230, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebski</LastName><ForeName>Val</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy-Bessard</LastName><ForeName>Anne-Claire</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Clinique Armoricaine de Radiologie, 21 Rue du Vieux Séminaire, 22015 Saint-Brieuc Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sehouli</LastName><ForeName>Jalid</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gynecology, European Competence Center for Ovarian Cancer, Charité-University Medicine of Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woie</LastName><ForeName>Kathrine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Haukeland University Hospital, N-5021 Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heywood</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vancouver Acute Department of Gynaecology, Rm 6207D Diamond Health Care Centre, 2775 Laurel St., Vancouver, BC V5Z 1M9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schauer</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Barmherzige Brüder Graz, Marschallgasse 12, 8020 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vergote</LastName><ForeName>Ignace</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Leuven Cancer Institute, University Hospital Leuven, Herestraat 49, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scambia</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Largo Agostino Gemelli 8, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrero</LastName><ForeName>Annamaria</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Academic Department Gynecologic Oncology, Mauriziano Hospital, Largo Turati 62, 10128 Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harter</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Gynecology & Gynecologic Oncology, Klinikum Essen Mitte, Henricistrasse 92, 45136 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pujade-Lauraine</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu, Oncologie, 1 Place du Parvis Notre-Dame, 75004 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedlander</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Oncology, Prince of Wales Hospital, Barker Street, Randwick, NSW 2013, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gynecol Oncol</MedlineTA><NlmUniqueID>0365304</NlmUniqueID><ISSNLinking>0090-8258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506643">liposomal doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>30IQX730WE</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>BG3F62OND5</RegistryNumber><NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Observational study</Keyword><Keyword MajorTopicYN="N">Platinum sensitive</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Recurrent ovarian cancer</Keyword><Keyword MajorTopicYN="N">Secondary cytoreductive surgery</Keyword><Keyword MajorTopicYN="N">Selection bias</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>07</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>09</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>09</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25281492</ArticleId><ArticleId IdType="pii">S0090-8258(14)01344-4</ArticleId><ArticleId IdType="doi">10.1016/j.ygyno.2014.09.017</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003138 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003138 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25281492
|texte= Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25281492" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |